Mechanism
Synthetic ACTH(4-10) analogue that crosses the blood-brain barrier and modulates BDNF, NGF, TrkB, glutamatergic signalling, and neuroinflammatory pathways to promote neuroprotection, synaptic plasticity, and cognitive function.
Category
Nootropic / Neuroprotection
Evidence Grade
C • Moderate
Status
Research compound. Approved in Russia for select neurological indications. Not approved by the FDA or EMA for human use.
Typical Reconstitution
10 mg vial + 2 mL BAC water (5,000 mcg/mL)
Route
Primarily intranasal
Documented Dosing
Standard: 300-900 mcg/day, divided into 2-3 intranasal doses
Cycle: 5-14 days, then reassess
Acute neurological studies: Higher short-term dosing has been used under clinical supervision
Description
Semax is a synthetic neuropeptide originally developed in Russia for neurological disorders and cognitive impairment. It has been investigated for ischemic stroke, traumatic brain injury, ADHD, cognitive decline, and optic nerve disorders. Research suggests it enhances neurotrophic signalling, particularly brain-derived neurotrophic factor (BDNF), while reducing neuroinflammation and supporting neuronal repair. Most human evidence comes from Russian clinical studies, with limited international replication. Although results are promising, Semax remains an investigational peptide outside Russia and is not approved by the FDA or EMA.